{"url_path":"/sec/qncx/8-k/2026-06-11/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-11","source_url":"https://www.sec.gov/Archives/edgar/data/1662774/0001193125-26-267862-index.html","accession_number":"0001193125-26-267862","cik":"0001662774","ticker":"QNCX","issuer_name":"Quince Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1662774/0001193125-26-267862-index.html","primary_entity_key":"0001662774","primary_entity_name":"Quince Therapeutics, Inc."},"word_count":465,"has_tables":true,"body_markdown":"Item 5.07\n\nSubmission of Matters to a Vote of Security Holders.\n\nThe Annual Meeting of Stockholders of Quince Therapeutics, Inc. (the “Company”) was held online via live webcast on June 11, 2026 (the “Annual Meeting”). At the Annual Meeting, there were present, in person virtually or by proxy, holders of 6,255,339 shares of common stock, or approximately 38.37% of the total outstanding shares eligible to be voted. The final voting results with respect to each proposal presented at the Annual Meeting is set forth below:\n\nProposal One - Election of Directors\n\nThe Company’s stockholders approved the election of one Class I director to the Board of Directors to serve until the 2029 annual meeting of stockholders and until her successor is duly elected and qualified or until her earlier death, resignation, disqualification or removal. The results of such vote were:\n\n \n\nNominee\n  \nVotes For\n  \nVotes Withheld\n  \nBroker Non-Votes\n\nJune Bray\n\n  \n2,430,964\n  \n216,735\n  \n3,607,640\n\nProposal Two - Approval of Amendment to the Certificate of Incorporation to Effect a Reverse Stock Split\n\nThe Company’s stockholders approved the amendment to the Company’s amended and restated certificate of incorporation to effect a reverse stock split of the Company’s issued and outstanding common stock at a ratio ranging from one-for-ten (1-for-10) to one-for-one hundred (1-for-100) with such reverse stock split to be effected at such time and date, if at all, as determined by the Company’s board of directors in its sole discretion. The results of such vote were:\n\n \n\nVotes For\n\n \n\nVotes Against\n\n \n\nAbstentions\n\n4,715,574\n \n1,517,896\n \n21,866\n\nProposal Three - Ratification of Selection of Independent Registered Accounting Firm\n\nThe Company’s stockholders ratified the selection of BDO USA, P.C. as the Company’s independent registered accounting firm for the fiscal year ending December 31, 2026. The results of such vote were:\n\n \n\nVotes For\n\n \n\nVotes Against\n\n \n\nAbstentions\n\n6,080,608\n \n111,522\n \n63,207\n\nProposal Four - Approval, on an advisory basis, of the compensation of the Company’s named executive officers\n\nThe Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the proxy statement. The results of such vote were:\n\n \n\nVotes For\n\n \n\nVotes Against\n\n \n\nAbstentions\n\n \n\nBroker Non-Votes\n\n2,504,778\n \n116,876\n \n26,044\n \n3,607,641\n\nProposal Five – Adjournment of Annual Meeting\n\nThe Company’s stockholders approved the adjournment or postponement of the Annual Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in favor of the foregoing proposals. The results of such vote were:\n\n \n\nVotes For\n\n \n\nVotes Against\n\n \n\nAbstentions\n\n5,236,032\n \n987,376\n \n31,929\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nQUINCE THERAPEUTICS, INC.\n\n \n\n \nBy:\n \n\n/s/ Dirk Thye\n\nDate: June 11, 2026\n \n\n \nName:\n \nDirk Thye\n\n \n\n \nTitle:\n \nChief Executive Officer and Chief Medical Officer"}